We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance
Read MoreHide Full Article
Esperion Therapeutics, Inc. (ESPR - Free Report) incurred a loss per share of $2.62 per share for the third quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of $2.86 per share. The company had recorded earnings of $3.07 per share in the year-ago period.
The company generated revenues of $14.4 million, beating the Zacks Consensus Estimate of $12.31 million. The company had recorded revenues of $3.8 million in the year-ago quarter.
Shares of Esperion were however down 7.4% in pre-market trading on Nov 2. In fact, Esperion’s stock has lost 58.2% so far this year compared with the industry’s 11.1% decrease.
Image Source: Zacks Investment Research
Quarter in Details
Esperion launched its first commercial drug — Nexletol — in March 2020 followed by Nexlizet in June in the United States. While Nexletol is a bempedoic acid monotherapy tablet, Nexlizet is a combination of bempedoic acid and Merck’s (MRK - Free Report) Zetia (ezetimibe) that are approved for treating elevated LDL-C (bad cholesterol).
Both these drugs received approval in Europe in April 2020. In Europe, Nexletol is available as Nilemdo and Nexlizet as Nustendi. Daiichi Sankyo, Esperion’s collaboration partner for Europe, launched the drugs in Germany in November 2020. Esperion records royalty on sales of its drugs in Europe.
Product revenues, solely from the United States, were $10.9 million in the third quarter compared with $3.3 million in the year-ago quarter and $10.3 million in the previous quarter. The company stated that prescriptions for its drugs were up 10% year over year.
The company recorded royalty revenues of $1.2 million during the reported quarter, compared with $1 million in the previous quarter. The drugs continued to show strong momentum in Europe. The item was included in Collaboration revenues, which were $3.5 million during the third quarter, compared with $0.5 million in the year-ago quarter.
Research and development (R&D) expenses decreased 28.3% from the year-ago period to $25.3 million due to lower clinical activities.
Selling, general and administrative expenses (SG&A) were down 19.5% year over year to $39.3 million.
As of Sep 30, 2021, Esperion had cash, cash equivalents and investment securities of $153.7 million compared with $219.2 million as of Jun 30, 2021.
Restructuring Plans
Last month, Esperion announced a plan to align its operational and expense structure, which will help the company to deliver better growth. The company plans targeted program savings and will reduce 40% of its workforce to lower its operating expense.
The company plans to streamline its sales force, and target cardiologists and primary care physicians for the promotion of its marketed drugs. It made the decision after a systematic review and is currently planning to focus on the commercialization of its two drugs as well as on the ongoing CLEAR Outcomes study, a CVOT study, evaluating Nexletol and Nexlizet in patients who have statin intolerability.
Guidance for 2021 & 2022
Esperion lowered its guidance for R&D and SG&A costs in 2021 and provided a new guidance for 2022. The company anticipates R&D expense for 2021 to be in the range of $110-$115 million compared with $120-$130 million expected previously. SG&A expense is expected to be between $195 million and $200 million, down from the previous expectation of $200-$210 million.
The company expects R&D expense for 2022 to be in the range of $100-$110 million, while SG&A expense is expected to be between $120 million and $130 million.
Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise
Xencor’s loss per share estimates have narrowed from 75 cents to 33 cents for 2021 and from $3.14 to $2.92 for 2022 in the past 30 days. The stock has risen 3.1% so far this year.
Neurocrine’s earnings per share estimates have moved north from $1.89 to $1.93 for 2021 and from $3.64 to $3.68 for 2022 in the past 30 days. The stock has risen 10.8% so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance
Esperion Therapeutics, Inc. (ESPR - Free Report) incurred a loss per share of $2.62 per share for the third quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of $2.86 per share. The company had recorded earnings of $3.07 per share in the year-ago period.
The company generated revenues of $14.4 million, beating the Zacks Consensus Estimate of $12.31 million. The company had recorded revenues of $3.8 million in the year-ago quarter.
Shares of Esperion were however down 7.4% in pre-market trading on Nov 2. In fact, Esperion’s stock has lost 58.2% so far this year compared with the industry’s 11.1% decrease.
Quarter in Details
Esperion launched its first commercial drug — Nexletol — in March 2020 followed by Nexlizet in June in the United States. While Nexletol is a bempedoic acid monotherapy tablet, Nexlizet is a combination of bempedoic acid and Merck’s (MRK - Free Report) Zetia (ezetimibe) that are approved for treating elevated LDL-C (bad cholesterol).
Both these drugs received approval in Europe in April 2020. In Europe, Nexletol is available as Nilemdo and Nexlizet as Nustendi. Daiichi Sankyo, Esperion’s collaboration partner for Europe, launched the drugs in Germany in November 2020. Esperion records royalty on sales of its drugs in Europe.
Product revenues, solely from the United States, were $10.9 million in the third quarter compared with $3.3 million in the year-ago quarter and $10.3 million in the previous quarter. The company stated that prescriptions for its drugs were up 10% year over year.
The company recorded royalty revenues of $1.2 million during the reported quarter, compared with $1 million in the previous quarter. The drugs continued to show strong momentum in Europe. The item was included in Collaboration revenues, which were $3.5 million during the third quarter, compared with $0.5 million in the year-ago quarter.
Research and development (R&D) expenses decreased 28.3% from the year-ago period to $25.3 million due to lower clinical activities.
Selling, general and administrative expenses (SG&A) were down 19.5% year over year to $39.3 million.
As of Sep 30, 2021, Esperion had cash, cash equivalents and investment securities of $153.7 million compared with $219.2 million as of Jun 30, 2021.
Restructuring Plans
Last month, Esperion announced a plan to align its operational and expense structure, which will help the company to deliver better growth. The company plans targeted program savings and will reduce 40% of its workforce to lower its operating expense.
The company plans to streamline its sales force, and target cardiologists and primary care physicians for the promotion of its marketed drugs. It made the decision after a systematic review and is currently planning to focus on the commercialization of its two drugs as well as on the ongoing CLEAR Outcomes study, a CVOT study, evaluating Nexletol and Nexlizet in patients who have statin intolerability.
Guidance for 2021 & 2022
Esperion lowered its guidance for R&D and SG&A costs in 2021 and provided a new guidance for 2022. The company anticipates R&D expense for 2021 to be in the range of $110-$115 million compared with $120-$130 million expected previously. SG&A expense is expected to be between $195 million and $200 million, down from the previous expectation of $200-$210 million.
The company expects R&D expense for 2022 to be in the range of $100-$110 million, while SG&A expense is expected to be between $120 million and $130 million.
Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise
Esperion Therapeutics, Inc. price-consensus-eps-surprise-chart | Esperion Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Esperion currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the same sector include Xencor (XNCR - Free Report) and Neurocrine Biosciences (NBIX - Free Report) . While Xencor sports a Zacks Rank #1 (Strong Buy), Neurocrine carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Xencor’s loss per share estimates have narrowed from 75 cents to 33 cents for 2021 and from $3.14 to $2.92 for 2022 in the past 30 days. The stock has risen 3.1% so far this year.
Neurocrine’s earnings per share estimates have moved north from $1.89 to $1.93 for 2021 and from $3.64 to $3.68 for 2022 in the past 30 days. The stock has risen 10.8% so far this year.